Biotech医药股

http://www.biopharmcatalyst.com/fda-calendar/
FDA calendar

http://bbs.wenxuecity.com/finance/3094583.html
炒Biotech医药股

ARNA 治疗肥胖症的药物, 已获得SFDA批准.

VVUS

KERX 治疗肾病的药物临床试验收报告,结果好.

ARIA 它有3个有希望的在研药物

.

http://bbs.wenxuecity.com/finance/3095034.html
小药股的比较赚钱的抄法：

http://bbs.wenxuecity.com/finance/3106965.html
GILD

http://bbs.wenxuecity.com/finance/3104396.html
ACAD

http://bbs.wenxuecity.com/finance/3231640.html
从单克隆抗体生化药股想开去，，，

ZT

Regeneron Pharmaceuticals (NASDAQ: REGN) is flying higher on Friday by 3.5% – it has produced gains of 10% this week – after Lazard Capital upgraded shares from Neutral to Buy. Apparently, Lazard likes the upside in its eye drug Eylea; this product is responsible for Regeneron’s 80% growth.

 

Just to be clear, when Regeneron was trading below $220 I was writing, tweeting, and screaming to buy the stock. But now, at $260, I think it’s getting a bit expensive. Look, I love the long-term potential of this company; I think that once its large pipeline develops that it will trade considerably higher; but at 15 times sales, I think there are better short-term opportunities elsewhere. But once the company’s rheumatoid arthritis drug Sarlimab is approved, my outlook is likely to change.

http://investorplace.com/2013/08/8-biotechnology-stocks-to-buy-now-insy-aria-pran/

 http://bbs.wenxuecity.com/finance/3291498.html
说两句：MNKD　(摸你裤底）

http://bbs.wenxuecity.com/finance/3332078.html
Earnings after the bell: $AVNR $DDC $HRB $IRET $MIND $NCS $PPHM

http://bbs.wenxuecity.com/finance/3299409.html
从Aria, VVUS说说药股新药的怪圈

http://bbs.wenxuecity.com/finance/3329192.html
2014 FDA Drug Approval Decision Calendar

http://bbs.wenxuecity.com/finance/3340605.html
年末总结MNKD, ARIA

http://bbs.wenxuecity.com/finance/3343326.html
可能翻倍的三只生物技术股2014年

http://bbs.wenxuecity.com/finance/3351815.html
谈谈生药股

http://bbs.wenxuecity.com/finance/3352931.html
戏说ＡＭＳＮ的风险与欺诈（１）

http://bbs.wenxuecity.com/finance/3359643.html
再来看看“高价”生药股是怎么泻的

http://bbs.wenxuecity.com/finance/3359550.html
看看“高价”生药股是怎么飙的。。。